Tri-Institutional PhD Program in Chemical Biology, Weill Cornell Medical College , New York, New York 10065, United States.
Departments of Molecular and Cellular Biology, Stem Cell and Regenerative Biology, and Chemistry and Chemical Biology, Harvard University and Harvard Medical School , Cambridge, Massachusetts 02138, United States.
J Am Chem Soc. 2017 Jun 7;139(22):7632-7639. doi: 10.1021/jacs.7b02988. Epub 2017 May 22.
The Ras proteins are essential GTPases involved in the regulation of cell proliferation and survival. Mutated oncogenic forms of Ras alter effector binding and innate GTPase activity, leading to deregulation of downstream signal transduction. Mutated forms of Ras are involved in approximately 30% of human cancers. Despite decades of effort to develop direct Ras inhibitors, Ras has long been considered "undruggable" due to its high affinity for GTP and its lack of hydrophobic binding pockets. Herein, we report a total chemical synthesis of all-l- and all-d-amino acid biotinylated variants of oncogenic mutant KRas(G12V). The protein is synthesized using Fmoc-based solid-phase peptide synthesis and assembled using combined native chemical ligation and isonitrile-mediated activation strategies. We demonstrate that both KRas(G12V) enantiomers can successfully fold and bind nucleotide substrates and binding partners with observable enantiodiscrimination. By demonstrating the functional competency of a mirror-image form of KRas bound to its corresponding enantiomeric nucleotide triphosphate, this study sets the stage for further biochemical studies with this material. In particular, this protein will enable mirror-image yeast surface display experiments to identify all-d peptide ligands for oncogenic KRas, providing a useful tool in the search for new therapeutics against this challenging disease target.
Ras 蛋白是参与细胞增殖和存活调节的必需 GTP 酶。突变的致癌形式的 Ras 改变效应因子结合和固有 GTP 酶活性,导致下游信号转导失调。突变形式的 Ras 参与了大约 30%的人类癌症。尽管几十年来一直努力开发直接的 Ras 抑制剂,但由于其与 GTP 的高亲和力和缺乏疏水性结合口袋,Ras 长期以来一直被认为是“不可成药的”。在此,我们报告了致癌突变体 KRas(G12V)的所有 l-和全 d-氨基酸生物素化变体的全化学合成。该蛋白使用基于 Fmoc 的固相肽合成合成,并使用组合的天然化学连接和异腈介导的激活策略组装。我们证明了 KRas(G12V)两种对映异构体都可以成功折叠并结合核苷酸底物和结合伙伴,并观察到对映体选择性。通过证明与相应对映体核苷酸三磷酸结合的 KRas 镜象形式的功能能力,本研究为使用该材料进行进一步的生化研究奠定了基础。特别是,这种蛋白质将能够进行镜像酵母表面展示实验,以鉴定致癌 KRas 的全 d 肽配体,为针对这一具有挑战性的疾病靶点的新治疗方法的寻找提供了有用的工具。